For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 225,255 | |||
| General and administrative | 61,554 | |||
| Other license income | 100,000 | |||
| Gains on sale of non-financial assets | 10,249 | |||
| Total operating expenses | 176,560 | |||
| Loss from operations | -176,560 | |||
| Interest and other income, net | 35,873 | |||
| Loss before provision for income taxes | -140,687 | |||
| Provision for income taxes | 515 | |||
| Net loss attributable to ordinary shareholders | -141,202 | |||
| Unrealized gain on investments, net | 140 | |||
| Total other comprehensive income | 140 | |||
| Comprehensive loss | -141,062 | |||
| Basic EPS | -0.8 | |||
| Diluted EPS | -0.8 | |||
| Basic Average Shares | 177,596,000 | |||
| Diluted Average Shares | 177,596,000 | |||
Structure Therapeutics Inc. (GPCR)
Structure Therapeutics Inc. (GPCR)